Article
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A focus on MAPK Pathway Inhibitors
Pediatric Drugs
(2023)
Abstract
Geerlinks, AV., Abla, O. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A focus on MAPK Pathway Inhibitors. Pediatric Drugs (2023): 1-11. PMID: 37204611
Histiocytic disorders are rare diseases defined by the clonal accumulation of a macrophage or dendritic cell origin. These disorders include Langerhans cell histiocytosis, Erdheim–Chester disease, juvenile xanthogranuloma, malignant histiocytoses, and Rosai–Dorfman–Destombes disease. These histiocytic disorders are a diverse group of disorders with different presentations, management, and prognosis. This review focuses on these histiocytic disorders and the role of pathological ERK signaling due to somatic mutations in the mitogen-activated protein kinase (MAPK) pathway. Over the last decade, there has been growing awareness of the MAPK pathway being a key driver in many histiocytic disorders, which has led to successful treatment with targeted therapies, in particular, BRAF inhibitors and MEK inhibitors.
Disciplines
Publication Date
May, 2023
Citation Information
Ashley Geerlinks. "Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A focus on MAPK Pathway Inhibitors" Pediatric Drugs (2023) Available at: http://works.bepress.com/ashley-geerlinks/12/